Cyclophosphamide, Ara-C and Topotecan (CAT) for Patients With Refractory or Relapsed Acute Leukemia

References

• Rowe J. M., Liesveld J. L. Treatment and prognostic- factors in acute myeloid leukemia. Baillieres Clinical Hematology 1996; 9: 81–105
   Google Scholar
• Estey E. H. Treatment of acute myelogenous leukemia and myelodysplastic syndromes. Seminars in Hematol-ogy 1995; 32: 132–151
   PubMed Web of Science ®Google Scholar
• Liu L. F. DNA topoisomerase poisons as antitumor drugs. Annual Review of Biochemistry 1989; 58: 351–375
   PubMed Web of Science ®Google Scholar
• Nagata H., Kaneda N., Furuta T., Sawada S., Yokokura T., Miyasaka T., Fukada M., Notake K. Action of 7-ethylcamptothecin on tumor cells and its disposition in mice. Cancer Treat Rep 1987; 71: 341–348
   PubMedGoogle Scholar
• Giovanella B. C., Stehlin J. S., Wall ME., Wani M. C., Nicholas A. W., Liu L. F., Silber R., Potmesil M. DNA topoisomerase I—targeted chemotherapy of human colon cancer in xenografts. Science 1989; 246: 1046–1048
   PubMed Web of Science ®Google Scholar
• Saltz L., Sirott M., Young C., Tong W., Niedzwiecki D., Tzy-Jyun Y., Tao Y., Trochanowski B., Wright P., Barbosa K. Phase I clinical and pharmacology study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempt at dose intensification using recombinant granulocyte colony-stimulating factor Ipublished erratum appears in J Natl Cancer Inst 1993 Nov 3;85(21): 1777). Journal of the National Cancer Institute 1993; 85: 1499–1507
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Grochow L. B., Hendricks C. B., Ettinger D. S., Forastiere A. A., Hurowitz L. A., McGuire W.P., Sar-torius S. E., Lubejko B. G., Kaufmann S. H., et al. Phase I and pharmacologic study of topotecan: a novel topoisomerase I inhibitor. Journal of Clinical Oncology 1992; 10: 647–656
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Adjei A., Donehower R. C., Gore S. D., Jones R. J., Burke P. J., Cheng Y. C., Grochow L. B., Kaufmann S. H. Phase I and pharmacodynamic study of the topoisomerase I-inhibitor topotecan in patients with refractory acute leukemia. Journal of Clinical Oncology 1994; 12: 2193–2203
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Beran M., Ellis A., Zwelling L., O'Brien S., Cazenave L., Roller C., Rios M. B., Plunkett W., Keating M. J. Phase I study of Topotecan, a new topoisomerase I inhibitor, in patients with refractory or relapsed acute leukemia. Blood 1993; 81: 1146–1151
   PubMed Web of Science ®Google Scholar
• Rowinsky E. K., Kaufmann S. H. Topotecan in combination chemotherapy. Seminars in Oncology 1997; 24: S20–11, S20–26
   Google Scholar
• Beran M., Estey E. H., O'Brien S., Cortes J., Koller C. A., Giles F. J., Kornblau S., Andreeff M., Vey N., Pierce S. R., Hayes K., Wong G. C., Keating M., Kantarjian H. 1999, Topotecan and cytarabine is an active combination regimen in myelodysplastic syndromes and chronic myelomonocytic leukemia. Journal of Clinical Oncology, In press
   Google Scholar
• Seiter K., Feldman E. J., Halicka H. D., Traganos F., Darzynkiewicz Z., Lake D., Ahmed T. Phase I clinical and laboratory evaluation of topotecan and cytarabine in patients with acute leukemia. Journal of Clinical Oncology 1997; 15: 44–51
   PubMed Web of Science ®Google Scholar
• Boothman D. A., Wang M., Schea R. A., Burrows H. L., Strickfaden S., Owens J. K. Posttreatment exposure to camptothecin enhances the lethal effects of x-rays on radioresistant human malignant melanoma cells. International Journal of Radiation Oncology, Biology, Phvs-ics 1992; 24: 939–948
   PubMed Web of Science ®Google Scholar
• Kano Y., Suzuki K., Akutsu M., Suda K., Inoue Y., Yoshida M., Sakamoto S., Miura Y. Effects of CPT-11 in combination with other anti-cancer agents in culture. International Journal of Cancer 1992; 50: 604–610
   PubMed Web of Science ®Google Scholar
• Giovanella B., Potmesil M., Wall M. E. Treatment of human cancer xenografts with camptothecin analog in combination with cytoxan or x-irradiation. Proc Am Assoc Cancer Res 1994; 35: 454, (Abstract #2711)
   Google Scholar
• Nitiss J. L., Rose A. M., Sykes K. C. DNA topoisomerase I sensitizes cells to DNA damage. Proc Am Assoc Cancer Res 1996; 37: 428, (Abstract #2923)
   Google Scholar
• Mattern M. R., Hofmann G. A., McCabe F. L., Johnson R. K. Synergistic cell killing by ionizing radiation and topoisomerase I inhibitor topotecan (SK&F 104864). Cancer Research 1991; 51: 5813–5816
   PubMed Web of Science ®Google Scholar
• Musk S. R., Steel G. G. The inhibition of cellular recovery in human tumour cells by inhibitors of topoisomerase. British Journal of Cancer 1990; 62: 364–367
   PubMed Web of Science ®Google Scholar
• Murren J. R., Anderson S., Fedele J., Pizzorno G., Bel-liveau D., Zelterman D., Burtness B. A., Tocino I., Flynn S. D., Beidler D., Cheng Y. C. Dose-escalation and pharmacodynamic study of topotecan in combination with cyclophosphamide in patients with refractory cancer. Journal of Clinical Oncology 1997; 15: 148–157
   PubMed Web of Science ®Google Scholar
• Saylors R. L., Stewart C. F., Zamboni W. C., Wall D. A., Bell B., Stine K. C., Vietti T. J. Phase I study of topotecan in combination with cyclophosphamide in pediatric patients with malignant solid tumors: a Pediatric Oncology Group Study. Journal of Clinical Oncology 1998; 16: 945–952
   PubMed Web of Science ®Google Scholar
• Cheson B. D., Cassileth P. A., Head D. R., Schiffer C. A., Bennett J. M., Bloomfield C. D., Brunning R., Gale R. P., Grever M. R., Keating M. J. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990; 8: 813–819
   PubMed Web of Science ®Google Scholar
• Estey E. Treatment of refractory AML. Leukemia 1996; 10: 932–936
   PubMed Web of Science ®Google Scholar
• Estey E., Kornblau S., Pierce S., Kantarjian H., Beran M., Keating M. A stratification system for evaluating and selecting therapies in patients with relapsed or primary refractory acute myelogenous leukemia [letter]. Blood 1996; 88: 756
   PubMed Web of Science ®Google Scholar
• Kantarjian H. M., Estey E. H., Keating M. A. New chemotherapeutic agents in acute myeloid leukemia. Leukemia 1996; 10(Suppl 1)S4–6
   PubMedGoogle Scholar
• Beran M., Estey E., O'Brien S. M., Giles F. J., Koller C. A., Kornblau S., Keating M., Kantarjian H. M. Results of topotecan single-agent therapy in patients with myelodysplastic syndromes and chronic myelomonocytic leukemia [In Process Citation]. Leuk Lymphoma 1998; 31: 521–531
   PubMed Web of Science ®Google Scholar
• Beran M., Kantarjian H., O'Brien S., Koller C., al-Bitar M., Arbuck S., Pierce S., Moore M., Abbruzzese J. L., Andreeff M., Keating M., Estey E. Topotecan. a topoisomerase I inhibitor, is active in the treatment of myelodysplastic syndrome and chronic myelomonocytic leukemia. Blood 1996; 88: 2473–2479
   PubMed Web of Science ®Google Scholar
• Hoogstraten B. Cyclophosphamide (Cytoxan) in acute leukemia, preliminary report. Cancer Chemother Rep 1960; 8: 116–119
   PubMedGoogle Scholar
• Pierce M., Shore N., Sitarz A., Murphy M. L., Louis J., Severo N. Cyclophosphamide therapy in acute leukemia of childhood. Cooperative study conducted by members of Children's Cancer Cooperative Group A. Cancer 1966; 19: 1551–1560
   PubMed Web of Science ®Google Scholar
• Freedman M. H., Finklestein J. Z., Gilchrist G. S., Hammond G. D., Higgins G. R., Hyman C. B., Shore N. A., Williams K.O., Karon M. R. Preliminary evaluation of cyclophosphamide (NSC-26271) and cytosine arabinoside (NSC-63878) in acute leukemia of children. Cancer Chemotherapy Reports - Part 1 1969; 53: 299–303
   PubMedGoogle Scholar
• Ansari B. M., Thompson E. N. Refractory leukemia treated with cytosine arabinoside and cyclophosphamide. Cancer 1973; 32: 294–297
   PubMed Web of Science ®Google Scholar
• Bodey G. P., Rodriguez V., Hart J., Freireich E. J. Therapy of acute leukemia with the combination of cytosine arabinoside (NSC-63878) and cyclophosphamide (NSC-26271). Cancer Chemotherapy Reports - Part 1 1970; 54: 255–262
   PubMedGoogle Scholar
• Uckun F. M., Stewart C. F., Reaman G., Chelstrom L. M., Jin J., Chandan-Langlie M., Waddick K. G., White J., Evans W. E. In vitro and in vivo activity of topotecan against human B-lineage acute lymphoblastic leukemia cells. Blood 1995; 85: 2817–2828
   PubMed Web of Science ®Google Scholar